Clinical trials

  • LY3537982 for KRAS G12C-mutant advanced solid tumors
  • RITUXIMAB for Waldenstrom's macroglobulinaemia
  • SIBEPRENLIMAB for Sjögren's syndrome
  • DURVALUMAB for Endometrial cancer
  • VENETOCLAX for Waldenström’s Macroglobulinemia
  • DABRAFENIB for Anaplastic thyroid cancer
  • ATEZOLIZUMAB for Muscle-invasive bladder cancer
  • Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA for Mucopolysaccharidosis type I (Hurler syndrome)
  • Clinical trial in Relapsed or refractory multiple myeloma
  • MEDI5752 for Metastatic soft tissue sarcoma
  • VENETOCLAX for Small lymphocytic lymphoma | Chronic lymphocytic leukemia
  • Fenebrutinib for Primary progressive multiple sclerosis